Stock Track | Madrigal Pharmaceuticals Soars 6.34% Pre-Market on Strong Q3 Revenue Growth and Rezdiffra Demand

Stock Track

Nov 04

Madrigal Pharmaceuticals (NASDAQ: MDGL) saw its stock surge 6.34% in pre-market trading following the release of its third-quarter 2025 financial results, which showcased significant revenue growth driven by strong demand for its drug Rezdiffra.

The company reported Q3 product revenue of $287.26 million, representing a substantial 362.03% increase compared to the same period last year. This impressive growth was primarily attributed to the increasing demand for Rezdiffra, Madrigal's flagship product. Despite the revenue surge, the company still reported a net loss of $114.19 million, or $5.08 per share, which was wider than analyst estimates.

In addition to the strong financial performance, Madrigal announced a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist, signaling potential future growth opportunities. The company also highlighted its recent launch of Rezdiffra in Germany following European Commission approval, further expanding its market reach. With Rezdiffra's patent protection extending to 2045 and plans to initiate clinical trials for the oral GLP-1 in the first half of 2026, investors appear optimistic about Madrigal's long-term prospects in the thriving biotech sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1117508451"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117508451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117508451?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117508451","market":"sg","top_or_hot":-1,"title":"Stock Track | Madrigal Pharmaceuticals Soars 6.34% Pre-Market on Strong Q3 Revenue Growth and Rezdiffra Demand","media":"Stock Track","content":"<p>Madrigal Pharmaceuticals (NASDAQ: MDGL) saw its stock surge 6.34% in pre-market trading following the release of its third-quarter 2025 financial results, which showcased significant revenue growth driven by strong demand for its drug Rezdiffra.</p>\n\n<p>The company reported Q3 product revenue of $287.26 million, representing a substantial 362.03% increase compared to the same period last year. This impressive growth was primarily attributed to the increasing demand for Rezdiffra, Madrigal's flagship product. Despite the revenue surge, the company still reported a net loss of $114.19 million, or $5.08 per share, which was wider than analyst estimates.</p>\n\n<p>In addition to the strong financial performance, Madrigal announced a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist, signaling potential future growth opportunities. The company also highlighted its recent launch of Rezdiffra in Germany following European Commission approval, further expanding its market reach. With Rezdiffra's patent protection extending to 2045 and plans to initiate clinical trials for the oral GLP-1 in the first half of 2026, investors appear optimistic about Madrigal's long-term prospects in the thriving biotech sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Madrigal Pharmaceuticals Soars 6.34% Pre-Market on Strong Q3 Revenue Growth and Rezdiffra Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Madrigal Pharmaceuticals Soars 6.34% Pre-Market on Strong Q3 Revenue Growth and Rezdiffra Demand\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-04 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Madrigal Pharmaceuticals (NASDAQ: MDGL) saw its stock surge 6.34% in pre-market trading following the release of its third-quarter 2025 financial results, which showcased significant revenue growth driven by strong demand for its drug Rezdiffra.</p>\n\n<p>The company reported Q3 product revenue of $287.26 million, representing a substantial 362.03% increase compared to the same period last year. This impressive growth was primarily attributed to the increasing demand for Rezdiffra, Madrigal's flagship product. Despite the revenue surge, the company still reported a net loss of $114.19 million, or $5.08 per share, which was wider than analyst estimates.</p>\n\n<p>In addition to the strong financial performance, Madrigal announced a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist, signaling potential future growth opportunities. The company also highlighted its recent launch of Rezdiffra in Germany following European Commission approval, further expanding its market reach. With Rezdiffra's patent protection extending to 2045 and plans to initiate clinical trials for the oral GLP-1 in the first half of 2026, investors appear optimistic about Madrigal's long-term prospects in the thriving biotech sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1117508451","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117508451","pubTimestamp":1762259809,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Madrigal Pharmaceuticals (NASDAQ: MDGL) saw its stock surge 6.34% in pre-market trading following the release of its third-quarter 2025 financial results, which showcased significant revenue growth...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"个股追踪|Madrigal Pharmaceuticals盘前飙升6.34%，因Q3营收强劲增长和Rezdiffra需求","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Madrigal Pharmaceuticals (NASDAQ: MDGL) saw its stock surge 6.34% in pre-market trading following the release of its third-quarter 2025 financial results, which showcased significant revenue growth driven by strong demand for its drug Rezdiffra.\nThe company reported Q3 product revenue of $287.26 million, representing a substantial 362.03% increase compared to the same period last year. This impressive growth was primarily attributed to the increasing demand for Rezdiffra, Madrigal's flagship product. Despite the revenue surge, the company still reported a net loss of $114.19 million, or $5.08 per share, which was wider than analyst estimates.\nIn addition to the strong financial performance, Madrigal announced a global licensing agreement with CSPC Pharma for an oral GLP-1 receptor agonist, signaling potential future growth opportunities. The company also highlighted its recent launch of Rezdiffra in Germany following European Commission approval, further expanding its market reach. With Rezdiffra's patent protection extending to 2045 and plans to initiate clinical trials for the oral GLP-1 in the first half of 2026, investors appear optimistic about Madrigal's long-term prospects in the thriving biotech sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}